Targeted Disease(s):
COVID-19
Purpose of Study:
A randomized, controlled, Phase 2b study to evaluate safety and efficacy of rivaroxaban(Xarelto®) for high risk people with mild COVID-19.
Study Dates:
September 1, 2020 - Ongoing
Type of Study:
Pre-Market
Study Design:
Controlled Design
Study Location:
Nationwide
Lead Institution:
Allergy & Asthma Medical Group and Research Center A P.C
Funding Source:
Bill & Melinda Gates Medical Research Institute
Sponsors:
Bill & Melinda Gates Medical Research Institute (Gates MRI)
Contact:
Silvia Cedillo
858.268.2368 ext 130
silviacedillo@allergyandasthma.com
ClinicalTrails.gov Identifier:
NCT04504032
